Cargando…

In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines

The effects of cisplatin (CDDP) and etoposide (ETP) in combination were evaluated in vitro and in vivo using small cell lung cancer cell lines. The combination effects in vitro were investigated using isohologram analysis. Used together, CDDF and ETP showed a synergistic effect against cell growth o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kondo, Hideki, Kanzawa, Fumihiko, Nishio, Kazuto, Saito, Shiro, Saijo, Nagahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1994
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919348/ https://www.ncbi.nlm.nih.gov/pubmed/7961107 http://dx.doi.org/10.1111/j.1349-7006.1994.tb02905.x

Ejemplares similares

Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW‐2189 in Cell Lines Resistant to Cisplatin and CPT‐11
por: Ogasawara, Hayato, et al.
Publicado: (1995)

Reversal of Cisplatin Resistance with Amphotericin B in a Non‐small Cell Lung Cancer Cell Line
por: Morikage, Toshihiko, et al.
Publicado: (1991)

Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin
por: Naruse, Ichiro, et al.
Publicado: (2002)

Characterization of a Human Small‐cell Lung Cancer Cell Line Resistant to a New Water‐soluble Camptothecin Derivative, DX‐8951f
por: Nomoto, Taisuke, et al.
Publicado: (1998)

The Mechanism of the Difference in Cellular Uptake of Platinum Derivatives in Non‐small Cell Lung Cancer Cell Line (PC‐14) and Its Cisplatin‐resistant Subline (PC‐14/CDDP)
por: Ohmori, Tohru, et al.
Publicado: (1993)

Characterization of a Taxol‐resistant Human Small‐cell Lung Cancer Cell Line
por: Ohta, Sei, et al.
Publicado: (1994)

Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines
por: Busch, Maike, et al.
Publicado: (2018)

Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene
por: Kurokawa, Hirokazu, et al.
Publicado: (1997)

Preferential Binding of E7010 to Murine β3‐Tubulin and Decreased β3‐Tubulin in E7010‐resistant Cell Lines
por: Iwamoto, Yasuo, et al.
Publicado: (1998)

A Topoisomerase II Inhibitor, NK109, Induces DNA Single‐ and Double‐strand Breaks and Apoptosis
por: Fukuda, Minoru, et al.
Publicado: (1996)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

In vitro Enhancement of Antitumor Activity of a Water‐soluble Duocarmycin Derivative, KW‐2189, by Caffeine‐mediated DNA‐repair Inhibition in Human Lung Cancer Cells
por: Ogasawara, Hayato, et al.
Publicado: (1997)

Enhancement of Cisplatin Sensitivity in High Mobility Group 2 cDNA‐transfected Human Lung Cancer Cells
por: Arioka, Hitoshi, et al.
Publicado: (1999)

Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519
por: Nakamura, Takashi, et al.
Publicado: (2001)

Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin
por: Meczes, E L, et al.
Publicado: (2002)

Rapid Polymerase Chain Reaction Assay to Detect Variation in the Extent of Gene‐specific Damage between Cisplatin‐ or VP‐16‐resistant and Sensitive Lung Cancer Cell Lines
por: Oshita, Fumihiro, et al.
Publicado: (1994)

Alteration of Type II Regulatory Subunit of cAMP‐dependent Protein Kinase in Human Cisplatin‐resistant Cells as a Basis of Collateral Sensitivity to 8‐Chloro‐cAMP
por: Nishio, Kazuto, et al.
Publicado: (1992)

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
por: Sun, Yan, et al.
Publicado: (2016)

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.
por: Zangemeister-Wittke, U., et al.
Publicado: (1998)

Determinants of Drug Response in a Cisplatin‐resistant Human Lung Cancer Cell Line
por: Fujiwara, Yasuhiro, et al.
Publicado: (1990)

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
por: Goto, K, et al.
Publicado: (2004)

Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo
por: Fukumoto, Hisao, et al.
Publicado: (1997)

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
por: Okamoto, H, et al.
Publicado: (2007)

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis
por: Jiang, Shiyu, et al.
Publicado: (2021)

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
por: Berghmans, Thierry, et al.
Publicado: (2017)

A Novel Antitumor Antibiotic, KW‐2189 Is Activated by Carboxyl Esterase and Induces DNA Strand Breaks in Human Small Cell Lung Cancer Cells
por: Ogasawara, Hayato, et al.
Publicado: (1994)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
por: Sekine, I, et al.
Publicado: (2008)

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
por: Hotta, Katsuyuki, et al.
Publicado: (2021)

A Computational Model for Quantitative Analysis of Cell Cycle Arrest and Its Contribution to Overall Growth Inhibition by Anticancer Agents
por: Kuh, Hyo‐Jeong, et al.
Publicado: (2000)

Characterisation of a vindesine-resistant human small-cell lung cancer cell line.
por: Ohta, S., et al.
Publicado: (1993)

Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer
por: Xiao, Xiaoguang, et al.
Publicado: (2015)

An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015)

CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver
por: Shimizu, Mikiko, et al.
Publicado: (2001)

Detection of Proteins that Recognize Platinum‐modified DNA Using Gel Mobility Shift Assay
por: Fujiwara, Yasuhiro, et al.
Publicado: (1990)

Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin.
por: Nishio, K., et al.
Publicado: (1990)

Combination Chemotherapy with Cyclophosphamide, Vincristine, Cisplatin and Etoposide(COPE) Combined with Radiotherapy for Small Cell Lung Cancer
por: Nam, Yong Jin, et al.
Publicado: (1995)

Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic non small cell lung cancer: An Indian study
por: Kamath, Mangesh P, et al.
Publicado: (2016)

LEVELS OF GLUTATHIONES TRANSFERASE π mRNA IN HUMAN LUNG CANCER CELL LINES CORRELATE WITH THE RESISTANCE TO CISPLATIN AND CARBOPLATIN
por: Nakagawa, Kazuhiko, et al.
Publicado: (1988)

Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6
por: Tatsumi, Yasuaki, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_iqjqc4i9s9itk2t5ignko4k6sr